Civik Thomas — SEC insider filings
SEC reporting owner CIK 1723092. 17 insider filings on record with FilingPulse; latest filed 2026-09-08.
Transaction summary — filings shown
Covers all 17 filings on record, filed 2021-04-13 to 2026-09-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 23,200 shares, $410,618 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: purchase of 7,500 shares @ $28.08 ($210,600) in Repare Therapeutics Inc., filed 2021-11-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Repare Therapeutics Inc. (RPTX) | Director | 6 | 1 leg · 7,500 sh · $210,600 | — | 5 |
| Pyxis Oncology, Inc. (PYXS) | CEO & Chairman of the Board, Director | 9 | 1 leg · 15,700 sh · $200,018 | — | 8 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) | President and CEO, Director | 2 | — | — | 3 |
Insider filings — Civik Thomas
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 2,503,050 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 250,956 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 690,131 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Repare Therapeutics Inc. (RPTX) | Disposition to issuer (D): 7,500 | EDGAR |
| 2025-04-02 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 36,979 (derivative) @ $0.98 | EDGAR |
| 2024-06-20 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 44,024 (derivative) @ $3.83 | EDGAR |
| 2023-06-12 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 27,200 (derivative) @ $0 | EDGAR |
| 2023-03-28 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 139,355 @ $0 | EDGAR |
| 2022-05-16 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 66,831 @ $0 | EDGAR |
| 2021-11-19 | 4 | Pyxis Oncology, Inc. (PYXS) | Purchase (P): 15,700 @ $12.74 | EDGAR |
| 2021-11-18 | 4 | Repare Therapeutics Inc. (RPTX) | Purchase (P): 7,500 @ $28.08 | EDGAR |
| 2021-10-12 | 4 | Pyxis Oncology, Inc. (PYXS) | Grant/award (A): 42,191 (derivative) @ $0 | EDGAR |
| 2021-09-09 | 4 | Repare Therapeutics Inc. (RPTX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Disposition to issuer (D): 68,971 @ $38 · Disposition to issuer (D): 480,000 (derivative) | EDGAR |
| 2021-04-13 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Tax withholding (F): 11,088 @ $37.94 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-04-07 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1723092 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs